Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HLN 
Haleon plc (HLN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: HLN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.63
1 Year Target Price $11.63
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.37% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 43.97B USD | Price to earnings Ratio 21.51 | 1Y Target Price 11.63 |
Price to earnings Ratio 21.51 | 1Y Target Price 11.63 | ||
Volume (30-day avg) 5 | Beta 0.24 | 52 Weeks Range 8.70 - 11.35 | Updated Date 09/16/2025 |
52 Weeks Range 8.70 - 11.35 | Updated Date 09/16/2025 | ||
Dividends yield (FY) 0.69% | Basic EPS (TTM) 0.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.81% | Operating Margin (TTM) 22.21% |
Management Effectiveness
Return on Assets (TTM) 4.61% | Return on Equity (TTM) 9.38% |
Valuation
Trailing PE 21.51 | Forward PE 18.05 | Enterprise Value 54532707269 | Price to Sales(TTM) 3.99 |
Enterprise Value 54532707269 | Price to Sales(TTM) 3.99 | ||
Enterprise Value to Revenue 3.65 | Enterprise Value to EBITDA 14.85 | Shares Outstanding 4474650112 | Shares Floating 8991803100 |
Shares Outstanding 4474650112 | Shares Floating 8991803100 | ||
Percent Insiders 0.02 | Percent Institutions 12.85 |
Upturn AI SWOT
Haleon plc
Company Overview
History and Background
Haleon plc was formed in July 2022 as a spin-off from GSK (GlaxoSmithKline). It focuses solely on consumer healthcare. GSK and Pfizer combined their consumer healthcare businesses in 2019, ultimately leading to the Haleon separation.
Core Business Areas
- Oral Health: Includes toothpaste, toothbrushes, and mouthwashes under brands like Sensodyne, Parodontax, and Polident. Focuses on sensitive teeth, gum health, and denture care.
- Pain Relief: Offers over-the-counter pain relievers such as Advil, Voltaren, and Panadol for headaches, muscle aches, and arthritis.
- Vitamins, Minerals and Supplements (VMS): Provides dietary supplements and vitamins through brands like Centrum, Caltrate, and Emergen-C, addressing nutritional needs and immune support.
- Respiratory Health: Offers over-the-counter treatments for colds, flu, and allergies under brands such as Theraflu and Robitussin.
- Digestive Health: Provides remedies for heartburn, indigestion, and other digestive issues. Brands include Tums and ENO.
Leadership and Structure
Brian McNamara is the CEO. The company has a board of directors and operates with a regional structure, reporting financial results by geographic region (North America, Europe, and Rest of World).
Top Products and Market Share
Key Offerings
- Sensodyne: Toothpaste for sensitive teeth; a global leader. Competitors include Colgate Sensitive, Crest Sensi-Relief. Significant market share, revenue is not public.
- Advil: Over-the-counter pain reliever; a major player in the ibuprofen market. Competitors include Bayer (Aleve), Johnson & Johnson (Tylenol). Significant market share, revenue is not public.
- Centrum: Multivitamin supplement brand; one of the most recognized multivitamin brands globally. Competitors include Bayer (One A Day), Nature Made. Significant market share, revenue is not public.
- Theraflu: Over-the-counter treatment for cold and flu symptoms. Competitors include Reckitt Benckiser (Lemsip), Procter & Gamble (Vicks). Significant market share, revenue is not public.
Market Dynamics
Industry Overview
The consumer healthcare industry is characterized by increasing self-medication trends, an aging population, and growing awareness of preventive healthcare. It is a large, fragmented market with strong growth potential.
Positioning
Haleon is a leading player in the consumer healthcare market, with a portfolio of well-known and trusted brands. It has a strong global presence and invests in innovation and marketing. Its competitive advantages lie in its brand recognition, scale, and expertise.
Total Addressable Market (TAM)
The global consumer healthcare market is estimated to be several hundred billion USD. Haleon plc is positioned to capture a significant share of this TAM through its diverse product portfolio and global reach.
Upturn SWOT Analysis
Strengths
- Strong brand portfolio
- Global presence
- Leading market positions
- Innovation capabilities
- Experienced management team
Weaknesses
- Relatively new standalone company
- High debt levels from spin-off
- Exposure to regulatory changes
- Dependence on key brands
Opportunities
- Growth in emerging markets
- Expanding e-commerce channels
- Acquisitions of smaller brands
- Product innovation
- Increasing self-medication trends
Threats
- Intense competition
- Pricing pressures
- Changing consumer preferences
- Economic downturns
- Product liability claims
Competitors and Market Share
Key Competitors
- JNJ
- BAYRY
- PG
Competitive Landscape
Haleon has a strong portfolio of leading brands, but faces intense competition from other large consumer healthcare companies. Its advantages include its global reach and strong brand recognition. Disadvantages may include high debt and competition with established players.
Major Acquisitions
Hydro Labs
- Year: 2023
- Acquisition Price (USD millions): 0
- Strategic Rationale: Minor investment for future product development.
Growth Trajectory and Initiatives
Historical Growth: Since its spin-off, Haleon has demonstrated organic revenue growth.
Future Projections: Analysts expect Haleon to continue to grow revenue in the mid-single digits, driven by innovation and expansion into emerging markets.
Recent Initiatives: Focusing on innovation with products and sustainability.
Summary
Haleon is a newly formed company with established brands that operate in a competitive global healthcare market. It has achieved growth since its creation. High debt from the spin-off and competition from others are the main areas to watch out for. Good management of the debt and competitive landscape will drive success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Haleon plc Investor Relations
- Company Press Releases
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is based on estimates and may vary. Financial figures are approximate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Haleon plc
Exchange NYSE | Headquaters - | ||
IPO Launch date 2022-07-22 | CEO & Executive Director Mr. Brian James McNamara | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 24561 | Website https://www.haleon.com |
Full time employees 24561 | Website https://www.haleon.com | ||
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.